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Background: Gly1057Asp polymorphism in insulin receptor substrate (IRS)-2 is related to insulin resistance and
diabetes mellitus (DM), which both contribute to the pathogenesis of coronary artery disease (CAD). Hence, we
hypothesize that Gly1057Asp polymorphism in IRS-2 is associated with CAD.
Methods: Patients receiving elective coronary angiography were enrolled. Significant stenosis is defined as a
luminal diameter stenosis greater than 50%. Patients without significant stenosis were defined as group A, and
those with significant stenosis in at least one major coronary artery were defined as group B. Genotypes were
determined by polymerase chain reaction/restriction fragment length polymorphism. Chi-square test and
multivariate logistic regression were used to evaluate the relationship between Gly1057Asp polymorphism in
IRS-2 and CAD. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated as a
representative of insulin resistance. Multiple linear regression was used to analyze the association between
Gly1057Asp polymorphism in IRS-2 and the HOMA-IR index.
Results: There were 170 patients in group A and 284 patients in group B. The Gly allele frequencies were 54.7% for
group A and 60.9% for group B (p = 0.077). The Gly/Gly + Gly/Asp genotype frequency was 74.1% for group A and
84.9% for group B (p = 0.007). After adjustments for conventional risk factors in multivariate logistic regression,
the odds ratio for CAD in patients with the Gly/Gly + Gly/Asp genotype was 2.008 [95% confidence interval
(95% CI) = 1.210-3.332, p = 0.007], using patients with the Asp/Asp genotype as a reference group. The concurrence
of Gly1057Asp polymorphism in IRS-2 with DM is correlated with occurrence of CAD. In multivariate logistic
regression, employing non-diabetics with the Asp/Asp genotype as a reference group, the odds ratio for CAD was
1.561 [95% CI = 0.517-4.713, p = 0.430] for diabetics with the Asp/Asp genotype, 1.922 [95% CI = 1.086-3.400,
p = 0.025] for non-diabetics with the Gly/Gly + Gly/Asp genotype, and 3.629 [95% CI = 1.820-7.236, p < 0.001] for
diabetics with the Gly/Gly + Gly/Asp genotype. There was no association between Gly1057Asp polymorphism in
IRS-2 and HOMA-IR index.
Conclusion: Gly allele at codon 1057 in IRS-2 is correlated with an increased susceptibility to CAD in the Taiwanese
population. There is a synergistic effect toward CAD between the pathogenicity of DM and that of the Gly allele.
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There is evidence that coronary artery disease (CAD) is
associated with genetic factors [1]. Both insulin resist-
ance [2-4] and diabetes mellitus (DM) [5] are risk factors
for CAD. Thus, the genetic variants involved in the de-
velopment of insulin resistance and DM may be asso-
ciated with the susceptibility to CAD.
Insulin binding to its receptors leads to activation of
several intracellular downstream effectors. Among these,
insulin receptor substrate (IRS) proteins are most impor-
tant [6]. Insulin activates the insulin receptor substrate/
phosphatidylinositol 3-kinase (IRS/PI3-K) pathway and
the Ras/mitogen-activated protein kinase (MAPK) path-
way. The IRS/PI3-K pathway mediates insulin-dependent
glucose transport, whereas the Ras/MAPK pathway pro-
motes insulin-mediated cell growth and proliferation. Re-
sistance in the glucose regulation pathway is referred to
as insulin resistance. Hyperinsulinemia occurs during in-
sulin resistance due to stimulation of pancreatic β-cell
activity. Other pathways are probably over-stimulated
due to hyperinsulinemia. The chronic effects of the hy-
perinsulinemia cause dyslipidemia, higher blood pres-
sure, or platelet hypercoagulation that contribute to CAD
pathogenesis [7].
Genetic polymorphism in the IRS plays a role in in-
sulin resistance related disorders [8]. Gly972Arg poly-
morphism caused by a single nucleotide polymorphism
(SNP) in IRS-1 is associated with impaired IRS-1 func-
tion [9], reduced insulin sensitivity [10], as well as an
increased susceptibility to type 2 DM [11] and CAD
[12]. IRS-2 is an alternative effector protein in the insu-
lin signaling pathway [13]. IRS-2 gene knockout mice
exhibit a phenotype similar to human type 2 DM [14]. In
humans, Gly1057Asp polymorphism in IRS-2 is caused
by a SNP in the IRS-2 gene (rs1805097) [15]. Middle-
aged glucose-tolerant Danish males who carry the Asp
allele have shown decreased serum insulin and C-peptide
concentrations during oral glucose tolerance tests [15].
A study of an Italian population reported that the Asp
allele increases the risk for type 2 DM in obese subjects,
while lean subjects have a decreased risk. Among non-
diabetic individuals, fasting C-peptide levels are inversely
related to the dosage of the Asp allele [16]. A study of
the Chinese Han population also concluded that lean
subjects with the Asp allele have a decreased risk for
DM, while obese subjects have an increased risk [17].
These data suggest that the Asp allele is associated with
a lower risk of insulin resistance and DM in lean indivi-
duals. On the contrary, the Gly1057Asp polymorphism
in IRS-2 is not associated with insulin resistance in
Finnish subjects [18]. The CC genotype of the -756C/T
SNP in the promoter region of IRS-2 is associated with
an increased susceptibility to CAD [19], which suggests
that genetic variants of IRS-2 may be associated withoccurrence of CAD. Until now, there are no reports of a
relationship between Gly1057Asp polymorphism in IRS-2
and CAD.
The frequency of the Gly allele at codon 1057 in IRS-2
is common in the Chinese Han population [18]. Since
most Taiwanese are descendants of Mainland Chinese,
they have similar genetic backgrounds. The prevalence
of Gly1057Asp polymorphism in IRS-2 is probably com-
mon in the Taiwanese. Because CAD shares common
risk factors with DM, it is possible that the genetic back-
grounds for CAD and DM are similar. Because the Asp
allele at codon 1057 in IRS-2 seems to be associated
with the low risk of insulin resistance and DM [15,16],
we hypothesize that the Asp allele plays a protective role
for CAD. In this study, we investigated the relationship
between Gly1057Asp polymorphism in IRS-2 and CAD
in the Taiwanese population.
Methods
Study subjects
A hospital-based cross-sectional study was conducted.
Patients older than 18 years old receiving coronary angi-
ography for stable angina pectoris, suspected CAD, or
pre-operation examination for structural heart disease
were enrolled. We aimed at investigating the association
between the Gly1057Asp polymorphism in IRS-2 and
coronary atherosclerosis rather than coronary throm-
bosis; thus, patients with acute myocardial infarction
were excluded. Besides, we intended to perform follow-
up angiography if indicated; patients with serum creatin-
ine levels greater than 221 μmol/L were excluded to
avoid contrast-induced nephropathy. Patient histories
of conventional CAD risk factors were obtained. The
definitions of hypertension (HTN), type 2 DM, and
hypercholesterolemia were in accordance with the rele-
vant reports [20-22]. In brief, a patient was considered
to have HTN if a seated blood pressure greater than
140/90 mmHg had been documented on at least two or
more office visits, or if antihypertensive medications had
been used. Type 2 DM was defined as being present if
the patient was under treatment for DM at the time of
admission to the study, or if their fasting blood glucose
levels had been greater than 7 mmol/L on two or more
separate occasions. Hypercholesterolemia was defined as
being present if the patient was being treated at the time
of enrollment or if their fasting blood total cholesterol
levels had been greater than 5.18 mmol/L. Body mass
index (BMI) was calculated using the formula: body
weight in kilograms divided by the square of body height
in meters (kg/m2). The homeostasis model assessment of
insulin resistance (HOMA-IR) index was calculated in
190 patients of the entire cohort. The HOMA-IR index
is a validated tool for estimating insulin resistance, and
is calculated as follows: fasting insulin (μIU/ml) × fasting
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drawn after at least 8 hours overnight fasting. Fasting
plasma sugar was checked by using the standard hexoki-
nase method. Radioimmunoassay was used to check the
fasting serum insulin levels. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki [25] and was approved by the ethics commit-
tee of National Cheng Kung University Hospital. After a
thorough explanation of the study and its contents, each
patient gave their informed consent.
Detection of Gly1057Asp polymorphism in IRS-2 by
polymerase chain reaction (PCR) and restriction fragment
length polymorphism (see Additional file 1 and 2)
Coronary angiography
Definition of CAD was as described previously [26]. Lu-
minal stenosis was defined as significant when the lu-
minal diameter of the major coronary artery, or one of
its major branches, showed a reduction of 50% or
greater. Major coronary arteries included left main ar-
tery, left anterior descending coronary artery, left cir-
cumflex coronary artery, and right coronary artery. The
major branches of right coronary artery included poster-
ior descending artery and posterolateral branch, the
major branch of left circumflex coronary artery was the
major obtuse marginal branch, and the major branch of
left anterior descending coronary artery was the major
diagonal branch. The decision of coronary arteries with
significant luminal stenosis was determined by two inde-
pendent investigators by visual determination.
Statistical analysis
The main object of current study is to evaluate the rela-
tionship between Gly1057Asp polymorphism in IRS-2
and CAD. Patients without significant luminal stenosis
were defined as group A and those with significant sten-
osis in at least one proper major coronary artery or its
major branches were defined as group B. Since the fre-
quency of Gly allele at codon 1057 in IRS-2 in diabetic
patients is about 65% for the Chinese Han population
[18], and assuming this Gly allele frequency for patients
in group B and a 10% difference for patients with the
Gly allele in group A, we estimated that 200 patients
were needed for each group to provide a two-tailed α of
0.05 and a power of 80%.
For continuous variables, results were presented as
mean with standard deviation (SD), and the differences
between groups were checked by the independent Stu-
dent T test. Categorical variables were presented using
frequency counts, and intergroup comparisons were ana-
lyzed by the chi-square test. A multivariate binary logis-
tic regression analysis was used for CAD prediction. All
variables were included in multivariate logistic analysis
(enter method). The effect of a risk factor was expressedas an odds ratio (OR) and a 95% confidence interval
(95% CI). A multiple linear regression analysis was used
to investigate the correlation of variables, including con-
ventional CAD risk factors and genotype, with the
HOMA-IR index. Unstandardized regression coefficients
(B coefficients) were calculated to show the relationship
between the variables and the HOMA-IR index. Standar-
dized regression coefficients (beta coefficients) were also
calculated to reveal the effect of each variable on the
HOMA-IR index; this allowed the magnitudes of the re-
gression coefficients to be compared and indicated which
variable played an important role [27]. The detailed
methods were described in Additional file 3 (see Ad-
ditional file 3).
The concern about multicollinearity in multivariate lo-
gistic or multiple linear regression analysis was checked
by calculating the variance inflation factor (VIF). Vari-
ables with a VIF value greater than 2.5 were considered
to have significant multicollinearity with other independ-
ent variables. Consequently, any independent variable
with a VIF value greater than 2.5 was considered to be
dropped from the analysis to avoid multicollinearity,
after taking into account the practical aspect and im-
portance of each variable. A p-value of less than 0.05
(two-tailed) was considered significant. All analyses were
done using SPSS for WINDOWS, version 12.0 (Chicago,
IL, United States).Results
Study subjects
In total, 454 patients were enrolled. The group A con-
tained 170 and the group B contained 284 patients.
Table 1 shows the clinical characteristics for the pa-
tient cohort. Patients in group B were older. There
were significant differences in HTN, DM, hypercholes-
terolemia history, smoking history, total cholesterol lev-
els, and serum creatinine levels between the two groups.
There was a male predilection in group B patients.
There were no differences in the BMI between the
two groups.Frequency of Gly1057Asp polymorphism in IRS-2 in
patient cohort
The frequency of Gly allele was 58.6% in total cohort.
The frequency of the Gly allele was slightly higher in
group B patients than in group A patients but not
reached the significant level. Observed genotype frequen-
cies were in Hardy-Weinberg equilibrium (p = 0.884 in
all, p = 0.358 in control patients, and p = 0.988 in CAD
patients). The frequency of the Gly/Gly and Gly/Asp
genotype was significantly higher in group B patients
than it was in group A patients (Table 2).






Age, years 59.0 ± 13.5 63.6 ± 10.7 <0.001
Body mass index (kg/m2) 25.5 ± 4.0 25.7 ± 3.4 0.668
Serum creatinine (μmol/L) 84.8 ± 23.7 94.2 ± 26.0 <0.001
Total cholesterol (mmol/L) 4.8 ± 0.9 5.0 ± 1.0 0.019
Male 82 (48.2%) 192 (67.6%) <0.001
Hypertension 94 (55.3%) 189 (66.5%) 0.021
Diabetes mellitus 33 (19.4%) 93 (32.7%) 0.002
Hypercholesterolemia history 74 (43.5%) 155 (54.6%) 0.026
Smoking history 43 (25.3%) 114 (40.1%) 0.002
Group A: control subjects.
Group B: CAD patients.
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IRS-2 and CAD
We analyzed the association between the Gly allele and
CAD using binary logistic regression analysis. Besides
univariate analysis, all conventional CAD risk factors
and genotype were included in multivariate analysis
(Table 3). We found that the Gly/Gly and Gly/Asp geno-
type is a significant risk factor for CAD. Other signifi-
cant risk factors for CAD were gender, age, DM, and
total cholesterol level. The VIF for each variable included
in the analysis was less than 2.0.
Relationship between the concurrence of Gly1057Asp
polymorphism in IRS-2 with DM and CAD
Our multivariate binary logistic regression showed that
the association of Gly allele with CAD is independent of
the influence of DM. We then evaluated the influence of
the concurrence of the Gly allele with DM on the sus-
ceptibility to CAD. We stratified the patients who had
DM and carried the Gly allele. The odds ratios for
patients with CAD were calculated using multivariate
binary logistic regression with adjustments for gender,Table 2 Allele and genotype frequency of Gly1057Asp
polymorphism of insulin receptor substrate-2





Gly 186 (54.7%) 346 (60.9%)
Asp 154 (45.3%) 222 (39.1%) 0.077
Genotype Genotype frequency






Gly/Gly + Gly/Asp 126 (74.1%) 241 (84.9%)
Asp + Asp 44 (25.9%) 43 (15.1%) 0.007
Group A: control subjects.
Group B: CAD patients.age, HTN, hypercholesterolemia history, smoking his-
tory, BMI, total cholesterol and serum creatinine levels.
DM was dropped from the analysis to avoid multicolli-
nearity with the variable genotype-DM interaction.
Employing non-diabetics with Asp/Asp genotypes as
a reference group, the odds ratio for CAD was 1.561
(p = 0.430) for diabetics with Asp/Asp genotypes, 1.922
(p = 0.025) for non-diabetics with Gly/Gly and Gly/Asp
genotypes, and 3.629 (p < 0.001) for diabetics with Gly/
Gly and Gly/Asp genotypes (Table 4).
Relationship between Gly1057Asp polymorphism in IRS-2
and insulin resistance
In 190 of the 454 total study subjects, we investigated
the relationship between Gly1057Asp polymorphism in
IRS-2 and insulin resistance, which was evaluated using
the HOMA-IR index. Among these patients, 82 (43.2%)
did not have and 108 (56.8%) had CAD. There were 149
(78.4%) patients with Gly/Gly and Gly/Asp genotypes
and 41 (21.6%) patients with Asp/Asp genotypes. Be-
tween these two patient groups (Gly/Gly and Gly/Asp
genotype vs. Asp/Asp genotype), there were no differ-
ences in CAD percentage, age, gender, HTN, smoking
history, BMI, HOMA-IR index, serum creatinine, or
total cholesterol levels. Fifty of 149 (33.6%) patients with
Gly/Gly and Gly/Asp genotypes had DM, while 7 of
41 (17.1%) patients with Asp/Asp genotypes had DM
(p = 0.041). Using multiple linear regression analysis, all
variables including conventional CAD risk factors and
genotype were included in analysis to check the relation-
ship between each variable and HOMA-IR index.
Employing the Asp/Asp genotypes as a reference, the
unstandardized and standardized regression coefficients
for Gly/Gly and Gly/Asp genotypes were −0.023 and
−0.029 (p = 0.678), respectively (Table 5). These results
suggested that there is no relationship between
Gly1057Asp polymorphism in IRS-2 and the HOMA-IR
index. DM, BMI, and serum creatinine were significantly
correlated with the HOMA-IR index. To investigate the
influence of obesity on the relationship between
Gly1057Asp polymorphism in IRS-2 and insulin resist-
ance, we defined a BMI value greater than 25 kg/m2 as
obesity according to the Asia-Pacific perspective redefin-
ing obesity in adult Asian [28], and repeated multiple
linear regression analysis. The unstandardized and stan-
dardized regression coefficients for Gly/Gly and Gly/Asp
genotypes were −0.028 and −0.035 (p = 0.608), which
suggested that there is no relationship between
Gly1057Asp polymorphism in IRS-2 and the HOMA-IR
index (see Additional file 4). We further performed mul-
tiple linear regression for both obese (n = 117) and non-
obese (n = 73) groups separately. We did not observe a
significant correlation between Gly1057Asp polymorphism
in IRS-2 and HOMA-IR index in either group. The VIF
Table 3 Logistic regression analysis of the relationship between Gly1057Asp polymorphism in IRS-2 and CAD*
Odds ratio (95% CI)
(Univariate analysis)




Asp/Asp(n = 87) reference reference
Gly/Gly + Gly/Asp(n = 367) 1.957 (1.220-3.139) 0.005 2.008 (1.210-3.332) 0.007
Male 2.240 (1.516-3.309) <0.001 1.969 (1.154-3.358) 0.013
Age, year 1.033 (1.016-1.050) <0.001 1.037 (1.017-1.057) <0.001
Hypertension 1.609 (1.089-2.376) 0.017 1.153 (0.738-1.803) 0.531
Diabetes mellitus 2.054 (1.305-3.232) 0.002 1.847 (1.133-3.009) 0.014
Smoking history 1.981 (1.302-3.012) 0.001 1.521 (0.912-2.536) 0.108
Hypercholesterolemia history 1.559 (1.063-2.286) 0.023 1.308 (0.841-2.032) 0.233
Body mass index(kg/m2) 1.012 (0.960-1.066) 0.667 1.992 (0.936-1.052) 0.796
Total cholesterol(mmol/L) 1.263 (1.037-1.538) 0.020 1.295 (1.028-1.631) 0.028
Serum creatitnine(μmol/L) 1.016 (1.007-1.024) <0.001 1.004 (0.995-1.014) 0.392
IRS: insulin receptor substrate; CAD: coronary artery disease; CI: confidence interval.
* Totally, 284 CAD patients and 170 control subjects were included in analysis.
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sion analysis was less than 2.0.Discussion
Our study demonstrated an association between
Gly1057Asp polymorphism in IRS-2 and CAD. Addi-
tionally, we produced evidence that the Gly1057Asp
polymorphism in IRS-2 interacts with DM in relation to
risk of CAD; there is a synergistic effect toward CAD be-
tween pathogenicity of DM and that of the Gly allele.Table 4 Logistic regression analysis of the relationship betwe
Odds ratio (95% CI)
(Univariate analysis)
Genotype-DM interaction
Nondiabetics:Asp/Asp(n = 68) reference
Diabetics:Asp/Asp(n = 18) 1.768 (0.612-5.105)
Nondiabetics:Gly/Asp + Gly/Gly(n = 261) 1.782 (1.041-3.050)
Diabetics:Gly/Asp + Gly/Gly(n = 107) 3.505 (1.830-6.711)
Male 2.240 (1.516-3.309)
Age, year 1.033 (1.016-1.050)
Hypertension 1.609 (1.089-2.376)
DM 2.054 (1.305-3.232)
Body mass index(kg/m2) 1.012 (0.960-1.066)
Hypercholesterolemia history 1.559 (1.063-2.286)
Smoking history 1.981 (1.302-3.012)
Total cholesterol(mmol/L) 1.263 (1.037-1.538)
Serum creatitnine(μmol/L) 1.016 (1.007-1.024)
DM: diabetes mellitus; CAD: coronary artery disease; CI: confidence interval.
* Totally, 284 CAD patients and 170 control subjects were included in analysis.
# DM was dropped from analysis because the variance inflation factors for DM and
factor for genotype-DM interaction was less than 2.0 if DM was removed from analIn our study population, the Gly/Gly and Gly/Asp
genotype frequencies for CAD patients were significantly
greater than in control subjects (Table 2). These results
suggest that the Gly allele positively correlates with the
occurrence of CAD, and therefore the Asp allele has a
protective effect against CAD. In multivariate binary lo-
gistic regression, the odds ratio of CAD was 2.008 for
patients with Gly/Gly and Gly/Asp genotypes and 1.847
for those with DM. These results suggest that the
Gly1057Asp polymorphism in IRS-2 is independent of
DM as a risk factor for CAD and that both Gly allele aten genotype-DM interaction and CAD*




0.292 1.561 (0.517-4.713) 0.430
0.035 1.922 (1.086-3.400) 0.025
<0.001 3.629 (1.820-7.236) <0.001
<0.001 1.981 (1.161-3.378) 0.012
<0.001 1.037 (1.017-1.057) <0.001
0.017 1.146 (0.742-1.814) 0.514
0.002 -# -#
0.667 0.993 (0.937-1.052) 0.802
0.023 1.302 (0.837-2.026) 0.241
0.001 1.516 (0.908-2.530) 0.112
0.020 1.301 (1.033-1.640) 0.026
<0.001 1.004 (0.995-1.014) 0.380
genotype-DM interaction were both greater than 10. The variance inflation
ysis.
Table 5 Linear regression analysis for prediction of HOMA-IR index








Gly1057Asp polymorphism in IRS-2
Asp/Asp(n = 41) reference reference reference
Gly/Gly(n = 69) + Gly/Asp(n = 80) 0.007 0.902 −0.023 −0.029 0.678
Age(year) −0.002 0.245 −0.003 −0.107 0.147
Diabetes mellitus 0.194 <0.001 0.151 0.213 0.003
Hypertension 0.103 0.037 0.078 0.115 0.121
Male 0.019 0.697 −0.032 −0.048 0.574
Smoking 0.013 0.800 −0.012 −0.017 0.830
Total cholesterol(mmol/L) 0.033 0.197 0.040 0.114 0.103
Serum creatinine(μmol/L) 0.002 0.019 0.003 0.206 0.007
Body mass index(kg/m2) 0.023 <0.001 0.017 0.189 0.008
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CAD (Table 3). Importantly, we found that the concur-
rence of Gly allele with DM is associated with an
increased susceptibility to CAD (Table 4). In patients
with either Asp/Asp genotypes or Gly/Gly and Gly/Asp
genotypes, the odds ratio for CAD in diabetics is almost
twice that of their non-diabetic counterparts, which is
compatible with the results reported in the Framingham
study [5]. In non-diabetics, the odds ratio for CAD in
those with Gly/Gly and Gly/Asp genotypes was 1.922,
which was about twice the ratio for those with Asp/Asp
genotypes. Similarly, in diabetics, the odds ratio for
CAD in those with Gly/Gly and Gly/Asp genotypes was
3.629, which was roughly twice the ratio for patients
with Asp/Asp genotypes. Further, the odds ratio for
CAD in diabetics with Gly/Gly and Gly/Asp genotypes
was 3.629, which was roughly four times the ratio found
in non-diabetics with Asp/Asp genotypes (Table 4).
These results suggest that the pathogenic ability of the
Gly allele to cause CAD is similar to that of DM. They
also suggest a synergistic effect between the pathogen-
icity of DM and that of the Gly allele. We found that
there was no correlation between Gly1057Asp poly-
morphism in IRS-2 and insulin resistance irrespective of
BMI values (Table 5) and obesity (Additional file 4).
These results probably exclude the possibility that the
Gly1057Asp polymorphism in IRS-2 contributes to CAD
through altering insulin resistance.
Several studies have already reported that genetic var-
iants caused by a SNP are associated with CAD, includ-
ing adiponectin receptor 2 gene [29,30], apolipoprotein
E gene [31], and genes related to regulation of blood
lipid levels [32]. In current study, we found the concur-
rence of Gly1057Asp polymorphism in IRS-2 with DM
affects the susceptibility to CAD. This interaction be-
tween Gly1057Asp polymorphism in IRS-2 and DMcould be a kind of gene-environmental or gene-gene
interaction. DM itself or genes contributory to develop-
ment of DM could interact Gly1057Asp polymorphism
in IRS-2 to influence the susceptibility to CAD. Similar
findings for interrelation of genetic variants and DM in
relation to disease traits have been reported. Genetic
variants of transcriptional factor 7-like 2 gene are asso-
ciated with CAD, which are significantly modulated by
the presence of type 2 DM [33]. Besides, the +183 A/G
polymorphism at the 3’-untranslated region of inter-
leukin (IL)-18 genes is associated with the circulating
IL-18 levels, especially apparent in patients with type 2
DM and metabolic syndrome [34]. The frequency of Gly
allele was 58.6% in our study subjects, which was ap-
proximately equal to that found in Chinese and Finnish
patients [18]. We found that Gly1057Asp polymorphism
in IRS-2 was not associated with insulin resistance,
which was consistent with studies of Finnish subjects
[18]. However, the Asp allele was reported to be corre-
lated with better insulin sensitivity in specific groups in
Danish [15] and Italian [16] populations. This discrep-
ancy may be due to differences in ethnics, or to hetero-
geneous demographic characteristics. Thus, further
investigation is needed to clarify the relationship be-
tween Gly1057Asp polymorphism in IRS-2 and insulin
resistance.
DM is a potent risk factor for CAD [5]. However, the
susceptibility to CAD is different among diabetic
patients. In diabetic patients concomitantly with other
conventional risk factors for CAD such as hypercholes-
terolemia and hypertension, the risk for cardiovascular
events in the following 5 to 10 years actually increases
much more than that for their counterparts [35-37].
Therefore, genetic screening for Gly1057Asp polymorph-
ism in IRS-2 may be a plausible method to early detect
diabetic patients with high susceptibilities to CAD.
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weakness of cross-sectional studies is an inability to in-
dicate causality because the predictor variable is not
shown to precede the outcome. However, the predictor
variable that we were interested in for this study,
Gly1057Asp polymorphism in IRS-2, was determined by
the time the study subjects were born. Hence, the results
of our study do demonstrate a causal relationship be-
tween Gly1057Asp polymorphism in IRS-2 and CAD.
Nonetheless, there were several limitations to this study.
First, the number of patients for our main objective, in-
vestigating the relationship between Gly1057Asp poly-
morphism in IRS-2 and CAD, was limited. The number
of control patients was 170, which is less than the calcu-
lated sample size of 200 patients required to achieve a
power of 80% with a two-tailed α of 0.05. Thus, a larger
scale study is needed to strengthen the present results.
The study was also limited in that it was a hospital-
based study. There may have been selection bias. Our
study subjects were not truly representative of the over-
all population. Therefore, a general population-based
study is needed to confirm our findings. Using multi-
slice computed tomography to screen coronary arteries
may be a feasible method for this purpose. When we
investigated the relationship between Gly1057Asp poly-
morphism in IRS-2 and insulin resistance we studied
only 190 of the total 454 patients. Also, we checked the
insulin resistance by calculating the HOMA-IR index ra-
ther than by using the gold standard method euglycemic
hyperinsulinemic clamp. Hence, our conclusion that
there is no correlation between Gly1057Asp polymorph-
ism in IRS-2 and insulin resistance should be further
confirmed by an investigation using euglycemic hyperin-
sulinemic clamp on a larger scale. Finally, although we
showed a correlation between Gly1057Asp polymorph-
ism in IRS-2 and CAD, we did not afford the molecular
mechanisms underlying this correlation.
Conclusions
We demonstrated that Gly allele at codon 1057 in IRS-2
is correlated with an increased susceptibility to CAD
and that there is a synergistic effect between this poly-
morphism and DM that increases a person’s suscepti-
bility to CAD. Individual genetic screening for this
common polymorphism may facilitate the management
of patients, especially for diabetic patients. Further well-
designed studies are needed to support our results and to
investigate possible clinical and therapeutic applications.
Additional files
Additional file 1: Detection of Gly1057Asp polymorphism in insulin
receptor substrate (IRS)-2 by polymerase chain reaction (PCR) and
restriction fragment length polymorphism. We performed genotypingby using PCR and restriction fragment length polymorphism. The
detailed methods we used were described.
Additional file 2: Identification of Gly1057Asp polymorphism of
insulin receptor substrate (IRS)-2 by polymerase chain reaction
(PCR) followed by restriction fragment length polymorphism. Results
of gel analysis for PCR and restriction fragment length polymorphism as
well as results of DNA sequencing were shown.
Additional file 3: Statistical analysis strategy for evaluation of
relationship between Gly1057Asp polymorphism in IRS-2 and
coronary artery disease (CAD) as well as insulin resistance. Detailed
methods for statistical analysis to evaluate relationship between
Gly1057Asp polymorphism in IRS-2 and coronary artery disease (CAD) as
well as insulin resistance were described.
Additional file 4: Linear regression analysis for prediction of
HOMA-IR index. We performed multiple linear regression analysis to
evaluate the relationship between HOMA-IR index and genotype as well
as conventional CAD risk factors, including age, gender, diabetes,
hypertension, smoking history, total cholesterol level, serum creatinine
level, and obesity. There was no relationship between genotype and
HOMA-IR index. Diabetes, serum creatinine level, and obesity were
significantly correlated to the HOMA-IR index.
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